Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Thank you very much. And hi everyone, welcome to Cinclus Pharma's third quarter 2025 earnings call. Here with me today, I also have our CFO, Maria Engström, and our R&D director, Margit Mahlapuu. We will present the latest developments from Q3 2025 and the upcoming news after, and after this presentation, we will be happy to answer any questions you may have. And before we begin, I would like to share a quick reminder with our listeners that during today's call, we may make forward-looking statements that involve known and unknown risks, uncertainties, and other important factors beyond the company's control that could cause the company's actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Please note that these forward-looking statements made during this call speak only as of today's date, and the company undertakes no obligation to update them to reflect subsequent events or circumstances other than to the extent required by law. So with that said, let's go then into the business. And many of you listeners know about our substance, Linaprazan glurate, which is our next-generation PCAB. We have definitely designed it to deliver unique 24-hour acid control. We also have the fastest onset of action observed to date in the class overall, and this presents a significant opportunity to position the product as best in class. We have finalized our Phase 2 with very strong results, demonstrating high healing rates, especially in severe erosive GERD patients. And now we have also initiated the Phase 3 program, which is definitely a very, very big milestone for us as a company. An important step towards approval later on. The first patient has been enrolled. You will learn more about that today. I would say that the first Phase 3 study remains significantly and clinically de-risked. We are also strongly backed by a clear regulatory strategy and extensive preclinical and clinical validations. Overall, the program looks very de-risked, and our commercial focus remains on patients with severe erosive GERD, where you find the highest unmet medical need and where Linaprazan glurate's superior acid control can deliver the greatest benefit. And I think that's important. And that is something we will further develop in the future as well. With this unique pharmacokinetic and pharmacodynamic profile, it provides strong differentiation compared to both PPIs currently on the market, as well as against all other PCABs both now and in the future. Additionally, this unique profile supports a specialty commercial model, which is also important for future commercialization. It's also interesting to observe that there's an increase in global momentum for PCABs overall, in regions where they have been launched. And now, we actually see that PCABs are available in over 30 countries. They are also replacing PPIs in markets where they have been launched and integrated into treatment guidelines for erosive GERD. So it looks very promising for the class overall. And moving to the next slide, where we're examining the correlation between healing and pH level, as you can see, there is a clear linear relationship between the 24-hour gastric acid control, at approximately pH four, and the healing of erosive GERD. The more intragastric pH stays above four, the higher the healing rates observed at four and eight weeks. This relationship is consistent across multiple studies and thousands of patients. When you look at PPIs, first-generation PCABs like Vonoprazan, or new compounds like Tegoprazan. As you can see, the relationship is evident everywhere, and overall, PPIs, the current standard of care, achieve approximately 60 to 70% acid control. The first generation of PCABs achieves something between 60% to 85% in acid control. We, as a unique next-generation product, come close to 100% or 96% in our studies. So it's really a unique possibility here. So this correlation reinforces that acid control is the key biomarker for clinical healing. And it's exactly where Linaprazan glurate differentiates with our superior 24-hour control. I mean with our superior 24-hour control and the fastest onset of action. So if you just look at the next slide, this slide is built on the previous one and illustrates how the correlation between pH above four and healing is fully aligned with the data from other studies and especially from the Vonoprazan US Phase 3 trial as shown here. From that study, Lansoprazole 30mg maintains pH around 66% of the time, resulting in approximately a 70% healing rate after eight weeks for severe patients. In comparison, in the same study, Vonoprazan 20mg achieved 85% pH above four, corresponding to approximately a 90% healing rate after eight weeks. It's spot on the line which we just mentioned. And what you can also see then, if you look into our study, where we have shown 96% pH above four, is that if you plot it into the same line here, it will translate into nearly complete healing for the most severe erosive GERD patients. This is very strong data. Reinforced acid control is the single most important determinant of healing. The superior pharmacodynamic profile of Linaprazan glurate provides a clear competitive advantage over both PPIs and other PCABs. So taking these together, this supports our Phase 3 dose selection and underpins our confidence in achieving best-in-class outcomes in the ongoing HEALING-1 study. I also wanted to mention a little bit about the overall market, which I introduced at the beginning of the presentation. Looking into the PCABs, the global PCAB market continues to expand rapidly, driven by strong demand for fast and durable acid control. And that also shows the unmet medical need. In the US, for instance, the launch of Phathom's Vonoprazan is progressing well. The company projects approximately 107 to 175 million USD in sales this year, and they already have nearly 800,000 prescriptions filled to date. Actually, they expect profitability next year, 2026. We also foresee and expect an NDA for Tegoprazan to be submitted this quarter by the company Sebela, which will further expand US category visibility, obviously. As I said initially, PCABs are now available in more than 25-30 markets worldwide, reflecting a broad clinical and commercial adaptation. In Japan, the first adopter market for PCABs accounts for approximately 44% of the entire acid blocker segment. And as you know, at the peak, they were close to 1 billion USD in sales only in Japan, while in South Korea, PCABs are already approved, representing approximately 23% of all acid blocker prescriptions, with double-digit annual growth. And it is definitely continuing to displace PPIs in other markets, such as India, where we're seeing rapid uptake. More than 20 brands launched, 13 licensing deals signed, and treatment guidelines updated to recommend first-line use for P-CABs in Mexico and Latin America. P-CABs have reached position number three in the market within just two years. Out. Pricing. Traditional PPIs. Everywhere P-CABs are launched, the future looks very promising. Combining these trends highlights a clear global shift towards P-CABs, reinforcing the strong commercial potential for Linaprazan glurate as the next-generation best-in-class therapy. So let's go in to the events during the quarter. During the third quarter, as we have already mentioned, we received positive feedback from regulatory authorities allowing us to initiate the Phase 3 HEEALING-1 study. And we're going to evaluate erosive GERD patients across all grades, focusing on the primary endpoint, where we aim to deliver superiority for the severe erosive GERD patients in four weeks. We have now initiated the Phase 3 trial, which will enroll approximately 500 patients in up to 100 clinical sites across seven European countries. We have dosed the first patients, and you will soon learn more about that. That actually happened during October. And that is, of course, an important milestone for us as a company and also for the substance. We have also presented an abstract at the biggest European congress in Berlin, highlighting the positive data from optimized tablet formulation developed for the Phase 3 and also for commercialization later on. In addition, an important step forward is the NDA. We received positive feedback from the FDA following the CMC meeting, confirming alignment on our manufacturing and quality strategy in preparation for an NDA submission. With that said, I will now hand over to Margit to present updates on the ongoing Phase 3 HEEALING-1 study, so please go ahead. Margit.
Thank you. I will give a brief summary of the status of our Phase 3 study. HEEALING-1. And as Christer already mentioned, the first patient in this trial was screened in mid-September and dosed in early October. In total, we aim to enroll about 500 patients across up to 100 clinical sites in seven European countries. Our primary endpoint is demonstrating superiority over the comparator, lansoprazole, in the healing of severe patients, specifically those classified as LA grade C and D, after four weeks of treatment. We will also monitor a number of key secondary endpoints where the focus is on healing and symptom relief, both at four and eight weeks of treatment, for patients with severe GERD, classified as NCD grade patients, as well as in all patients categorized as LA grade A to D. Overall, the patient recruitment has started very well and is fully aligned with our projections. On the right side of the slide, you'll see the line diagram where the planned recruitment is shown in green, and the actual recruitment rate is shown in yellow. You can see that the actual and planned screening of patients are fully aligned. As of mid-November, we have recruited approximately 10% of patients, which is according to our plan, as expected in the beginning of the trial. Recruitment is generally slower at the beginning as the sites are being activated, but as the trial progresses, recruitment accelerates. So top-line results from HEEALING-1 are anticipated in the second half of 2026, and after these results have been obtained, we will start a second healing study and a maintenance study, which will proceed both in Europe and the US. And now, on this slide, you see the seven countries participating in the HEEALING-1 trial. Those countries are listed on your left side, and on the right side of the slide, you see where the clinical sites are localized. Here, every red flag indicates a city where we have clinical sites. In many cities, we have numerous sites. So, the number of flags does not correspond to the number of active sites. We have also decided to add some additional sites that have expressed interest in joining the trial, and we expect regulatory approval for these sites in early spring 2026. So now I will hand over to discuss the financials.
Thank you. Margit. Let me go to the Q3 financial highlights. We ended the third quarter with a cash position of 540 million SEK, providing us with a solid runway into the Phase 3 program. Cash flow for the quarter was minus 49 million SEK, mainly reflecting increased R&D spending as the HEALING-1 Phase 3 study is now underway. R&D expenses totaled approximately 46 million SEK, including the first patient-in milestone payment of 3.5 million SEK. R&D represented 86% of total operating expenses, compared to an average of 83% over the past eight quarters, underscoring our continued investment focus on clinical execution. We also saw an increase in the number of coworkers, primarily due to the addition of specialized consultants supporting the Phase 3 program and ongoing regulatory activities. Overall, our operating loss for the quarter was approximately 44 million SEK, in line with expectations and consistent with the company's planned growth phase. So, moving on to the year-over-year financial comparison. Net sales totaled 9.7 million SEK in the third quarter. This primarily reflects the periodization of the upfront payment from Zentiva related to the outlicensing agreement for Europe. The recognition follows the cost allocation across the ongoing Phase 3 program. Operating expenses increased by 14.7 million SEK year over year, mainly due to the initiation of the Phase 3 study, where the 3.5 million SEK milestone for the first patient was included. Ebit was -44 million SEK compared with -39 million SEK in the same quarter last year, driven by the higher R&D spend associated with the start of the pivotal study. Financial net improved by 0.7 million SEK, primarily due to interest income on cash holdings and favorable foreign exchange effects. Net profit for the quarter was -40.7 million SEK, compared to -36.5 million SEK last year. This also reflects the higher operating costs for the Phase 3 execution. Going to the balance sheet, the cash, as I said earlier, ended at 540 million SEK at the end of the period, compared with 644 million SEK at the same time last year. This follows, of course, our increased R&D activity. With the Phase 3 study, non-current assets increased by 9.6 million SEK, mainly relating to the leasing of new office spaces. Other current assets rose by 24.7 million SEK, driven by prepayments to the CRO. The Phase 3 CRO and some CMC activities led to non-current liabilities increasing by 55.9 million SEK. This was linked to the Zentiva contract liability, representing deferred revenue beyond one year. Current liabilities increased by 50.6 million SEK, reflecting the short-term portion of the Zentiva contract. Overall, our financial position remains strong with sufficient resources to support the ongoing phase three trial and advance our preparations toward commercial readiness. And then we go to the shareholder slide. And this slide shows the structure. At the end of September 2025, the 15 largest shareholders together hold approximately 56% of the company shares, demonstrating a stable and long-term oriented ownership base. Our cornerstone IPO investors remain significant shareholders, including Trill Impact Ventures, the 4th AP Fund, and Link Investment and Venture. These investors have continued to provide strong institutional support since the IPO, reflecting confidence in Cinclus Pharma's long-term value creation potential. Our founding shareholders Peter Ng, Kjell Andersson, Mikael Dahlström's estate, Nylof Holding AB, and Lennart Hansson collectively hold about 14% of the company, maintaining close alignment with the company's mission. Australia. The cornerstone investors account for roughly 24% of the shares, which, together with the founders, represent nearly 40% combined ownership. This consistent and engaged shareholder base provides both stability and strategic continuity as we advance Linaprazan glurate through late-stage development and prepare for commercialization. Over to you, Christine.
Okay. Thank you. So just to summarize, then, the financial statements indicate that when it comes to the run rate, we are financially secured through 2027 for the readout of the healing One study. The first Phase 3 trial is estimated to yield top-line results in the second half of 2026. This looks promising. All the other milestones reflect, I would say, a steady execution across clinical, regulatory, and CMC fronts, as well as financially. This is definitely a strong foundation as we advance Linaprazan glurate through the first Phase 3 trial. Before we leave this meeting and open for questions, I would like to highlight our upcoming event on December 11th, titled 'Healing the Unhealed: Redefining Acid Control in Erosive GERD.' The session will feature Professor Prateek Sharma, a world-renowned gastroenterologist, educator, and researcher who has authored more than 550 publications and contributed extensively to advancing the diagnosis and management of erosive GERD diseases. Professor Sharma will discuss the current burden and clinical impact of GERD and erosive GERD, and the strengths and limitations of PPIs. The emerging role of PCABs in improving acid control and healing erosive disease. An illustrative patient case that underscores real-world challenges and unmet needs. We look forward to an informative session. And with that said, I will now open for questions. Q and A session.
If you wish to ask a question, please dial the Pound Key on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Joseph Headen from WR Securities. Please go ahead.
Good morning. Thank you for taking my questions. You mentioned that PCABs are taking a growing share of the market, and I'm just wondering if that has any implications for future trial designs. So, you've got a superiority study in HEALING-1 versus lansoprazole. Do you anticipate that there will be a need to change that? Should you proceed to the Healing-2 study and use Vonoprazan as a comparator? Or do you think that trial design still holds up? Thanks.
Okay. Good question. What we can say is that, of course, from both a commercial point of view and a regulatory point of view, we will not change the comparator. In this, we will use the same comparator as the other PCABs have used, lansoprazole. So, we will have an indirect comparison. The reason why we stay with PPIs is mostly from a regulatory point of view, because we need to have the registered products in the market. When we set up the studies, we cannot, from a regulatory point of view, compare with a drug that is not approved, for instance, in Europe. So, we need to stick with this. So, but of course, as I also tried to describe here earlier, the key aspect here is definitely the acid control. And since the biomarker with acid control in relation to healing is so strong and linear, the most important factor is to deliver the best acid controlling class. And that will, of course, end up with a strong position. And that is the argument, actually, why we will also have a very good rationale behind having excellent healing as well as symptom control for these severe patients. And of course, we are also looking into factors in the trial to become superior in healing, but also in symptom relief. So that will definitely be a differentiation factor that is not delivered by the other PCABs. We will also include this when we have the data. The hope is to include this in the label. The ambition is to include it in the label. And that by itself will also differentiate us from others who have non-inferior labels.
Okay. Thank you. And perhaps if I could just ask one on the market dynamics or. Yes, please explain what is happening in the period. Over, over. While you're still running the Phase 3 trials, with Tegoprazan potentially launching in the meantime, how do you see, particularly in the US, things changing in terms of the uptake of related drugs?
Well, that's irrelevant. Firstly, we can say that before entering the US, in Europe we might be the first PCAB on the market. It looks possible. But let's see, that is the first step in the US. It looks like we can be number three. And therefore we have always planned to have a product that is designed to deliver the best acid control, which is the benchmark in the market, which is proven to have a reason to be in the market. We definitely will focus on all the severe patients where there is still an unmet medical need, and that will also be the case in the future. You see, if Tegoprazan is the best PCAB, what it seems to be when it comes to acid control, Vonoprazan is the except for ours. Lennart Hansson. In Tegoprazan, it appears they have slightly less acid control compared to Vonoprazan. In that case, they will not add any additional value to Vonoprazan. Of course, when we enter the market, our ambition is to become best in class, and there will always be patients who are not healed by the first-generation PCABs. But we also know that the market is very dynamic. So you know that in Vonoprazan studies, 25% of the patients relapse within six months. And it's higher figures. What we understand in Tegoprazan is that it has slightly less acid control compared to Vonoprazan. Therefore, the patient will return to the physicians again after relapsing. So in that position, you definitely have a switch possibility. And since there are so many patients, specifically discussing the severe patients, we're talking about 4 or 5 million patients in the US. And definitely, there will be space for a superior acid control product, even though it will not be first. So the market will be there, and it will definitely still be a very big, dynamic market when we enter.
While you're still running the Phase 3 trials, with Tegoprazan potentially launching in the meantime, how do you see things changing in terms of uptake of relative drugs, particularly in the US? Thank you very much.
Thank you.
The next question comes from Georg Björk from ABG. Please, go ahead.
Yes. Hi, this is George. Thank you for taking my questions. I have two. So besides modeling a financial runway into 2027, could you provide any additional guidance on how opex will increase as the HEALING-1 trial ramps up? I'm particularly interested in the phasing between Q4 and Q1. And secondly, you keep hearing. Phathom's share price has really rallied lately, while Cinclus' share price is relatively flat since June. You are obviously at different stages, but still, it would be interesting if you're able to share thoughts or comments about that. Thank you.
Yes, of course. Normally, as you have seen, we have already provided guidance. I mean, we are financed with current cash into 2027. As you see, the burn rate we currently have in Q3 was a little bit less than 50 million. And what you could see is that, of course, this will differ a little bit from quarter to quarter depending on the payment schedules for the CRO. But I mean, I would say that it is approximately 50 million, which is what you would expect. And that is if you look into it, but it will differ slightly from quarter to quarter. So that is the first answer. The second answer on the Phathom stock price. I mean, that is, of course, very problematic for me to answer. But what you could say is that it's interesting to see. Thanks to their advancement and improvement in the launch, the market is obviously looking into that, and that's the reason why their market cap is increasing, and of course, the gap between their market cap and our market cap has increased. And, I mean, we have now delivered on what we have said we should deliver. And I mean, now we have the Zentiva deal in hand. And the collaboration looks very promising. And they, after extensive due diligence, actually chose our substance, which is definitely a validation. We have now initiated the start of the clinical study, specifically the Phase 3 trial. And that also appears to be going according to plan, which is good. And we foresee a readout of that trial in the second half of next year. There are numerous signs indicating improvement, along with the increasing awareness and prescriptions of PCABs globally. I would say that the time will come for us as well, but it is definitely very challenging for us to predict. But obviously we are delivering what we are supposed to do. And eventually, I suppose we will also gain from that when it comes to market cap.
Thank you.
As a reminder, if you wish to ask a question, please dial the pound key on your telephone keypad. The next question comes from Oscar Hefin Lamb from Stifel. Please go ahead.
Hi team. Thank you for taking my question. Just a quick question on my side. You mentioned possible additional sites to be activated. How many are we talking about? And will these also be in Eastern Europe?
Yes. We are considering that when you conduct clinical studies, you always need to be planning for the next steps ahead. And that's what we do. We make sure that we deliver the results in the second half of 2026. So this is just a mitigation strategy. But we're talking about ten to fifteen additional sites approximately. Can you help me here?
Yes. And also for regulatory reasons. We primarily want to open new sites in the countries which are already included in the trial because the regulatory process will be faster.
But yes, just to mention, I mean, we are still very confident with the current sites. We will deliver the top line in the second half of 2026. This is more of a precaution to ensure we are always prepared if something happens in the future. So it's nothing more than that.
Yes. Okay. Got it. Thank you.
There are no more questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.
Okay. Let's see. We have some questions from the written submissions. We have some updates on the situation in China. What happens in China? Do you have any response from Chinese patients yet? No. We are waiting for the reimbursement price and reimbursement process in China. It should come during this year. Normally, it takes up to a year. Normally, it takes a year to get price and reimbursement in China. And this is also the case here. So we expect to have the launch next year in China. So, these are the plans for China. Okay. Yes. And then the indication, if there is any indication, that we should achieve superiority in Phase 3. Well, I think it's important to remember here that our primary endpoint is superiority versus PPI in the first Phase 3 trial. And we have the capability to start with very high efficacy. So the chances to reach that are very, very good. The likelihood is considered very high and favorable. Therefore, definitely. And that is not only based on indications, we are also basing that, of course, on the Phase 2 trial results that we have. Really good healing data is already there. We deliver a superiority versus PPI in the post-hoc analysis. So now we're going to repeat that. But it's also based on the biomarker I mentioned regarding acid control. But it's also based on clinical data from other Phase 3 trials, like the Vonoprazan trials. We have combined these chances to reach this and made a very conservative diagnosis for this. So it looks very, very promising. So we are confident that we can reach superiority in the Phase 3 trial. Yes. And I asked for clarification on the Col event. It's an online event. Absolutely. So, we will send out the press release with the contacts and the links for that event in the coming weeks. So you will have it as well. So it's an online event open for everyone. Okay. I think we will stop there for now. And if there are no other questions, I thank you for your interest in Cinclus Pharma. And wish you a good day. Thank you very much. Goodbye.



















